Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: When, where and how?

Arnaud Trébucq, D. A. Enarson, C. Y. Chiang, A. Van Deun, A. D. Harries, F. Boillot, A. Detjen, P. I. Fujiwara, S. M. Graham, I. Monedero, I. D. Rusen, H. L. Rieder

研究成果: 雜誌貢獻文章同行評審

114 引文 斯高帕斯(Scopus)


Xpert® MTB/RIF offers new and important possibilities for the diagnosis of sputum smear-negative tuberculosis (TB) and/or rifampicin (RMP) resistance, and many are encouraging rapid and widespread implementation. This simple test can be implemented almost everywhere, and it provides results within a few hours. In low-income countries (LICs), however, its cost, environmental limitations (stable and regular electricity, adequate room temperature) and difficulties involved in supply and maintenance are major obstacles. While it may be suitable for major reference hospitals, operational research is needed to evaluate the test and its additional yield above high-quality smear microscopy and clinical algorithms before its use at the peripheral level. In the meantime, direct microscopy should remain the initial diagnostic test for TB suspects. In most LICs, the prevalence of RMP resistance among new TB patients is very low; an Xpert MTB/RIF result indicating RMP resistance will thus always need confirmation by another test. In a population at high risk of RMP resistance (>15%), however, the positive predictive value for RMP resistance by Xpert MTB/RIF is high, and identification of RMP resistance is an excellent proxy for multidrug-resistant TB (MDR-TB). The assay should be widely used for this purpose if, and only if, excellent MDR-TB management is available, both for ethical reasons and to reduce the risk of extensively drug-resistant TB.

頁(從 - 到)1567-1571
期刊International Journal of Tuberculosis and Lung Disease
出版狀態已發佈 - 12月 2011

ASJC Scopus subject areas

  • 肺和呼吸系統醫學
  • 傳染性疾病


深入研究「Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: When, where and how?」主題。共同形成了獨特的指紋。